Literature DB >> 12969313

Regulation of secondary lymphoid organ development by the nuclear factor-kappaB signal transduction pathway.

Falk Weih1, Jorge Caamaño.   

Abstract

In primary lymphoid organs, such as thymus and bone marrow, B and T lymphocytes differentiate from lymphoid stem cells into mature albeit naïve effector cells. In contrast, secondary lymphoid organs, such as the spleen, lymph nodes, and Peyer's patches (PPs), provide an environment that enable lymphocytes to interact with each other, with accessory cells, and with antigens, resulting in the initiation of antigen-specific primary immune responses. Recently, the analysis of gene-knockout mice has shed light on the signaling pathways, cellular requirements, and molecular mechanisms involved in secondary lymphoid organ development. In particular, signals that converge on the nuclear factor-kappaB (NF-kappaB) pathway have been demonstrated to play an important role in both early developmental steps as well as maintenance of secondary lymphoid organ structures. Analysis of the histopathological changes in secondary lymphoid tissues of mice lacking individual Rel/NF-kappaB family members, upstream kinases, and receptors strongly indicates that activation of the recently described alternative NF-kappaB pathway by membrane-bound lymphotoxin, via p52-RelB heterodimers, plays a major role during initiation steps of secondary lymphoid organ development. Induction of the classical p50-RelA NF-kappaB activity, as exemplified by tumor necrosis factor receptor signaling, clearly also contributes, but seems to be involved primarily in later developmental step, such as the proper cellular and structural organization of B-cell follicles.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12969313     DOI: 10.1034/j.1600-065x.2003.00064.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  84 in total

Review 1.  Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED): a model disease to study molecular aspects of endocrine autoimmunity.

Authors:  P Peterson; J Pitkänen; N Sillanpää; K Krohn
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

2.  Alternative nuclear functions for NF-κB family members.

Authors:  Lluís Espinosa; Anna Bigas; Maria Carmen Mulero
Journal:  Am J Cancer Res       Date:  2011-02-16       Impact factor: 6.166

Review 3.  Roles of the NF-kappaB pathway in lymphocyte development and function.

Authors:  Steve Gerondakis; Ulrich Siebenlist
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-23       Impact factor: 10.005

4.  Role of lymphotoxin and homeostatic chemokines in the development and function of local lymphoid tissues in the respiratory tract.

Authors:  Javier Rangel-Moreno; Damian Carragher; Troy D Randall
Journal:  Inmunologia       Date:  2007

Review 5.  Nuclear initiated NF-κB signaling: NEMO and ATM take center stage.

Authors:  Shigeki Miyamoto
Journal:  Cell Res       Date:  2010-12-28       Impact factor: 25.617

6.  RelA repression of RelB activity induces selective gene activation downstream of TNF receptors.

Authors:  Emilie Jacque; Thierry Tchenio; Guillaume Piton; Paul-Henri Romeo; Véronique Baud
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-28       Impact factor: 11.205

7.  Functional validation of genes implicated in lymphomagenesis: an in vivo selection assay using a Myc-induced B-cell tumor.

Authors:  Duonan Yu; Diana Cozma; Andrea Park; Andrei Thomas-Tikhonenko
Journal:  Ann N Y Acad Sci       Date:  2005-11       Impact factor: 5.691

8.  Regulation of p53 tumour suppressor target gene expression by the p52 NF-kappaB subunit.

Authors:  Katie Schumm; Sonia Rocha; Jorge Caamano; Neil D Perkins
Journal:  EMBO J       Date:  2006-09-21       Impact factor: 11.598

Review 9.  EDA signaling and skin appendage development.

Authors:  Chang-Yi Cui; David Schlessinger
Journal:  Cell Cycle       Date:  2006-09-14       Impact factor: 4.534

10.  RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow.

Authors:  Jingjing Xu; Peng Zhou; Wenjuan Wang; Aining Sun; Feng Guo
Journal:  J Mol Med (Berl)       Date:  2013-09-17       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.